Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus nab-paclitaxel and cisplatin for locally advanced hypopharyngeal cancer
ChiCTR2200055939Phase 2Not yet recruiting
- Sponsor
- The Sixth Medical Center of the Chinese People's Liberation Army General Hospital
- Start
- Jan 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, paclitaxel and cisplatin in squamous cell carcinoma of the hypopharynx, sponsored by The Sixth Medical Center of the Chinese People's Liberation Army General Hospital. Primary endpoint: Recurrence-free survival. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
03
Conditions
squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on ChiCTR2200055939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055939.